Opioid Use DisorderPhilly NavSTARNCT06634277
Philly NavSTAR Implementation Trial
A study testing NavSTAR (Philly adaptation) in people with Opioid Use Disorder, run by Friends Research Institute, Inc. at 2 sites in United States.
Trial summary
Patient Navigation (PN) interventions following hospitalization can reduce the differences that certain groups have been trying to access opioid use disorder treatment. These differences, which affect racial minority groups the most, contribute to the opioid overdose epidemic. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Opioid Use Disorder
- What is being tested?
- NavSTAR (Philly adaptation)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 2 sitesUnited States
- Study dates
- 9 Aug 2024to 31 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age 18 or older;
- current DSM-5 criteria for moderate to severe OUD;
- willing and able to provide informed consent in English.
Who cannot join
- enrollment in OUD treatment 30-days prior to hospitalization;
- residency outside the City of Philadelphia;
- pregnancy;
- planned discharge to a long-term inpatient care facility (e.g., hospice);
- hospitalization for a suicide attempt.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Jefferson Health
Philadelphia, Pennsylvania, 19107
Friends Research Institute
Philadelphia, Pennsylvania, 19125
About this study
Official title: Implementing a Patient Navigation Intervention Across a Health System to Address Treatment Entry Inequities
Patient Navigation (PN) interventions following hospitalization can reduce the differences that certain groups have been trying to access opioid use disorder treatment. These differences, which affect racial minority groups the most, contribute to the opioid overdose epidemic. However, delivering PN interventions on a wide scale requires many resources and coordination across institutions. This will use an evidence-based process to find solutions to these significant barriers by engaging community, hospital, and patient partners. This study is being conducted to learn more about how to implement NavSTAR, a patient navigation intervention for people with opioid use disorder, across a health system. Our research team showed in a previous study with 400 participants that NavSTAR significantly increased entry into opioid use disorder treatment, reduced readmissions to the hospital, and was highly cost- effective compared to treatment as usual. This study will first pilot NavSTAR with 32 patient participants across 4 hospitals in the City of Philadelphia. Then, we will conduct a large trial with 720 patient participants to see if we can reach people who need the intervention, and create a sustainable plan to continue the intervention after the grant award period.
Read the detailed description
Opioid agonist treatment (OAT) is protective against overdose, yet less than 20% of people with opioid use disorder (OUD) engage in such treatment. Hospital utilization is high among people with OUD and can be a 'reachable moment' to initiate OAT. However, most hospitals lack the capacity to follow up with patients after discharge. Theory-based, empirically supported patient navigator (PN) interventions following hospital discharge reduce inequities in accessing community-based OAT by helping patients navigate complex systems of care. However, challenges persist in implementing PN interventions on a wide scale, as they require coordination across institutions, data sharing, dedicated personnel, and community resources. This is especially true in settings that reach diverse, resource-challenged communities. To bring these interventions to scale, strategies are needed to assess factors that influence PN implementation in hospitals to increase feasibility, reach, and sustainability. Testing innovative implementation strategies for PN interventions has the potential for significant impact, as it will demonstrate implementation success of an intervention that can address the opioid epidemic in real-world settings and close the research-to-practice translation gap. The proposed study is a type II hybrid implementation-effectiveness trial of Navigation Services To Avoid Rehospitalization (NavSTAR). Our research team showed in a single-site randomized trial with 400 participants that NavSTAR significantly increased OAT entry, reduced readmissions, and was highly cost-effective compared to treatment as usual. The present study will test an Implementation Facilitation (IF) strategy following Proctor's conceptual model using an external facilitator and an internal local clinical champion to provide training, resources, and performance feedback to implement NavSTAR in four hospitals. We hypothesize that engaging stakeholders (including patients, clinicians, and community leaders) in an IF strategy will create and test an implementation process that is feasible, acceptable, and effective in expanding access to OAT post-discharge. The R61 phase will conduct process mapping to identify existing hospital workflow and then refine an IF strategy through sequential pilot trials at 4 hospital sites in preparation for the R33 phase. The team's NavSTAR operations manual will be adapted to the sites to train the existing staff. R61 milestones include the creation of an implementation toolkit and data-sharing agreements.
The developmental R61 phase will focus on needs assessment and identifying IF strategies for system-wide adoption of NavSTAR in preparation for the R33 trial phase. This will be accomplished through four inter-related processes: 1) Process mapping with the CAB and CAP, 2) Conducting qualitative interviews to gain diverse stakeholder input, 3) Modifying the IF strategy, and 4) Conducting four short-duration, iterative pilot testing cycles in four hospitals to examine the IF strategy for feasibility and acceptability. Pilot testing will occur with existing personnel (master's level social workers) utilizing the NavSTAR manual of operations. Interviews with current participants in the pilot testing, organizational stakeholders, navigators, and clinician champions will be conducted both before and after the pilot testing cycles.
Aim 1: Providers, staff, organizational leadership, and patients at the four hospitals will be asked to participate in the study (N=40) by completing interviews about current navigation/ discharge processes and optimal IF strategies.
Aim 2: Patients will be recruited across four hospitals (8 at each hospital) to conduct a pilot trial (N=32) of NavSTAR implementation. The CAB/CAP feedback, stakeholder interviews, and results of the pilot testing cycles will inform the final implementation toolkit used in the R33 phase.
- Conditions
- Opioid Use Disorder
- Being tested
- NavSTAR (Philly adaptation)
- Keywords
- patient navigation
- Medical subject headings
- Opioid-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NavSTAR (Philly adaptation)Behavioural
Patient Navigation
| Study group | Role | What they receive |
|---|---|---|
| NavSTAR | Experimental | NavSTAR is a Patient Navigation service model to reduce internal and external barriers to recommended service engagement. It includes motivational interventions in tandem with proactive barrier resolution, targeting areas of addiction, medical, self-care, and basic needs. Receives: Behavioral: NavSTAR (Philly adaptation) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Opioid Agonist Treatment (OAT) initiation
Post-discharge OAT initiation will be measured by self-report at follow-up, with verification through records where applicable (e.g., Community Behavioral Health system).
Measured: 3 months
Secondary outcomes (10)
Acceptability: Extent to which the intervention will be deemed acceptable by participants
Acceptability will be measured by the Acceptability of Intervention Measures Scale.
Measured: 3 months
Appropriateness: Extent to which the intervention will be deemed appropriate by participants
Appropriateness will be measured using the Intervention Appropriateness Measure scale
Measured: 3 months
Changes in Psychological distress from baseline to 3 months
Kessler-6 Psychological Distress Scale (K6) will be used to assess how participants have been feeling (nervous, hopeless, restless, depressed, worthless, etc) during their last 30 days.
Measured: Baseline to 3-month follow-up
Opioid use (oral fluid)
Proportion of participants with positive oral fluid drug testing for opioids.
Measured: 3 months
Changes in Social Support from Baseline to Follow-up
Social support will be measured using the Social Support Scale to determine the extent to which services influenced social support.
Measured: Baseline to 3 month follow-up
Change in Recovery Capital from baseline to follow-up
Recovery capital will be assessed using the BARC-10 scale.
Measured: Baseline to 3 month follow-up
Changes in Quality of Life from Baseline to Follow-up
Quality of life will be measured via the WHOQOL-BREF instrument.
Measured: Baseline to 3 month follow-up
Self-reported days of opioid use in the past 30 days
Self-reported days of non-medical opioid use in the past 30 days will be assessed at each interview.
Measured: Baseline to 3 month follow-up
Hospital Utilization
Information on acute care hospital utilization (including Emergency Department visits and Inpatient Admissions) will be assessed using health records and self-report (in the event of inconsistency, objective data will dominate).
Measured: 3 months
Feasibility: Demonstrated ability to enroll participants in the intervention
Feasibility will be measured by enrollment rate (Target 8 participants per month/per hospital), calculated as the number of eligible participants relative to the number screened. This is an implementation outcome measured in the aggregate (not patient-level)
Measured: From enrollment until end of follow-up (10 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2024
- Study start9 Aug 2024
- Primary completion26 Jul 2025
- Study completion31 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Opioid Use DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single group pilot study with sequential implementation in 4 hospitals
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Friends Research Institute, Inc.
- Sponsor type
- University, hospital or other
- Collaborators
- Thomas Jefferson University, National Institute on Drug Abuse (NIDA)
- Responsible party
- Sponsor
- Investigators
- Karen Alexander, PhD, Principal investigator, Friends Research Institute, Inc.Jan Gryczynski, PhD, Principal investigator, Friends Research Institute, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06634277
- Sponsor's protocol ID
- R61DA059033
- Other IDs
- R61DA059033
- Acronym
- Philly NavSTAR
- Status last verified
- Jun 2025
- First submitted
- 3 Feb 2024
- Last updated
- 29 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Because this is a feasibility pilot to inform a subsequent study, there is no plan to share IPD for the feasibility pilot. Interested researchers can nonetheless contact the PIs to discuss data sharing.
Publications
Gryczynski J, Nordeck CD, Welsh C, Mitchell SG, O'Grady KE, Schwartz RP. Preventing Hospital Readmission for Patients With Comorbid Substance Use Disorder : A Randomized Trial. Ann Intern Med. 2021 Jul;174(7):899-909. doi: 10.7326/M20-5475. Epub 2021 Apr 6.
PubMed 33819055
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementing a Patient Navigation Intervention Across a Health System to Address Treatment Entry Inequities
- ClinicalTrials.gov ID
- NCT06634277
- Acronym / sponsor ID
- Philly NavSTAR / R61DA059033
- Conditions
- Opioid Use Disorder
- Keywords
- patient navigation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Friends Research Institute, Inc.University, hospital or other
- Collaborators
- Thomas Jefferson University, National Institute on Drug Abuse (NIDA)
- Study start
- 9 Aug 2024 (actual)
- Primary completion
- 26 Jul 2025 (actual)
- Study completion
- 31 Aug 2025 (actual)
- First posted
- 9 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patient Navigation (PN) interventions following hospitalization can reduce the differences that certain groups have been trying to access opioid use disorder treatment. These differences, which affect racial minority groups the most, contribute to the opioid overdose epidemic. However, delivering PN interventions on a wide scale requires many resources and coordination across institutions. This will use an evidence-based process to find solutions to these significant barriers by engaging community, hospital, and patient partners. This study is being conducted to learn more about how to implement NavSTAR, a patient navigation intervention for people with opioid use disorder, across a health system. Our research team showed in a previous study with 400 participants that NavSTAR significantly increased entry into opioid use disorder treatment, reduced readmissions to the hospital, and was highly cost- effective compared to treatment as usual. This study will first pilot NavSTAR with 32 patient participants across 4 hospitals in the City of Philadelphia. Then, we will conduct a large trial with 720 patient participants to see if we can reach people who need the intervention, and create a sustainable plan to continue the intervention after the grant award period.
Detailed description
Opioid agonist treatment (OAT) is protective against overdose, yet less than 20% of people with opioid use disorder (OUD) engage in such treatment. Hospital utilization is high among people with OUD and can be a 'reachable moment' to initiate OAT. However, most hospitals lack the capacity to follow up with patients after discharge. Theory-based, empirically supported patient navigator (PN) interventions following hospital discharge reduce inequities in accessing community-based OAT by helping patients navigate complex systems of care. However, challenges persist in implementing PN interventions on a wide scale, as they require coordination across institutions, data sharing, dedicated personnel, and community resources. This is especially true in settings that reach diverse, resource-challenged communities. To bring these interventions to scale, strategies are needed to assess factors that influence PN implementation in hospitals to increase feasibility, reach, and sustainability. Testing innovative implementation strategies for PN interventions has the potential for significant impact, as it will demonstrate implementation success of an intervention that can address the opioid epidemic in real-world settings and close the research-to-practice translation gap. The proposed study is a type II hybrid implementation-effectiveness trial of Navigation Services To Avoid Rehospitalization (NavSTAR). Our research team showed in a single-site randomized trial with 400 participants that NavSTAR significantly increased OAT entry, reduced readmissions, and was highly cost-effective compared to treatment as usual. The present study will test an Implementation Facilitation (IF) strategy following Proctor's conceptual model using an external facilitator and an internal local clinical champion to provide training, resources, and performance feedback to implement NavSTAR in four hospitals. We hypothesize that engaging stakeholders (including patients, clinicians, and community leaders) in an IF strategy will create and test an implementation process that is feasible, acceptable, and effective in expanding access to OAT post-discharge. The R61 phase will conduct process mapping to identify existing hospital workflow and then refine an IF strategy through sequential pilot trials at 4 hospital sites in preparation for the R33 phase. The team's NavSTAR operations manual will be adapted to the sites to train the existing staff. R61 milestones include the creation of an implementation toolkit and data-sharing agreements.
The developmental R61 phase will focus on needs assessment and identifying IF strategies for system-wide adoption of NavSTAR in preparation for the R33 trial phase. This will be accomplished through four inter-related processes: 1) Process mapping with the CAB and CAP, 2) Conducting qualitative interviews to gain diverse stakeholder input, 3) Modifying the IF strategy, and 4) Conducting four short-duration, iterative pilot testing cycles in four hospitals to examine the IF strategy for feasibility and acceptability. Pilot testing will occur with existing personnel (master's level social workers) utilizing the NavSTAR manual of operations. Interviews with current participants in the pilot testing, organizational stakeholders, navigators, and clinician champions will be conducted both before and after the pilot testing cycles.
Aim 1: Providers, staff, organizational leadership, and patients at the four hospitals will be asked to participate in the study (N=40) by completing interviews about current navigation/ discharge processes and optimal IF strategies.
Aim 2: Patients will be recruited across four hospitals (8 at each hospital) to conduct a pilot trial (N=32) of NavSTAR implementation. The CAB/CAP feedback, stakeholder interviews, and results of the pilot testing cycles will inform the final implementation toolkit used in the R33 phase.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single group pilot study with sequential implementation in 4 hospitals
| Arm | Type | Receives |
|---|---|---|
| NavSTAR | Experimental | Behavioral: NavSTAR (Philly adaptation)NavSTAR is a Patient Navigation service model to reduce internal and external barriers to recommended service engagement. It includes motivational interventions in tandem with proactive barrier resolution, targeting areas of addiction, medical, self-care, and basic needs. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- age 18 or older;
- current DSM-5 criteria for moderate to severe OUD;
- willing and able to provide informed consent in English.
Key exclusion criteria (5 listed)
- enrollment in OUD treatment 30-days prior to hospitalization;
- residency outside the City of Philadelphia;
- pregnancy;
- planned discharge to a long-term inpatient care facility (e.g., hospice);
- hospitalization for a suicide attempt.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NavSTAR (Philly adaptation)Patient Navigation | Behavioural | NavSTAR |
Primary outcome
Opioid Agonist Treatment (OAT) initiation
Time frame: 3 months
Post-discharge OAT initiation will be measured by self-report at follow-up, with verification through records where applicable (e.g., Community Behavioral Health system).
10 secondary outcomes
Acceptability: Extent to which the intervention will be deemed acceptable by participants
Time frame: 3 months
Appropriateness: Extent to which the intervention will be deemed appropriate by participants
Time frame: 3 months
Changes in Psychological distress from baseline to 3 months
Time frame: Baseline to 3-month follow-up
Opioid use (oral fluid)
Time frame: 3 months
Changes in Social Support from Baseline to Follow-up
Time frame: Baseline to 3 month follow-up
Change in Recovery Capital from baseline to follow-up
Time frame: Baseline to 3 month follow-up
Changes in Quality of Life from Baseline to Follow-up
Time frame: Baseline to 3 month follow-up
Self-reported days of opioid use in the past 30 days
Time frame: Baseline to 3 month follow-up
Hospital Utilization
Time frame: 3 months
Feasibility: Demonstrated ability to enroll participants in the intervention
Time frame: From enrollment until end of follow-up (10 months)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2025.
- Background: PubMed 33819055Gryczynski J, Nordeck CD, Welsh C, Mitchell SG, O'Grady KE, Schwartz RP. Preventing Hospital Readmission for Patients With Comorbid Substance Use Disorder : A Randomized Trial. Ann Intern Med. 2021 Jul;174(7):899-909. doi: 10.7326/M20-5475. Epub 2021 Apr 6.
- Individual participant dataSharing planned: No. Because this is a feasibility pilot to inform a subsequent study, there is no plan to share IPD for the feasibility pilot. Interested researchers can nonetheless contact the PIs to discuss data sharing.
Related trials for Opioid Use Disorder
Active, not recruiting
Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
Neonatal Abstinence Syndrome, Opioid-use Disorder
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Active, not recruitingPhase 1/2
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
Opioid Use Disorder, Opioid Withdrawal
Not yet recruitingPhase 4
Examining Analgesic Synergy and Efficacy in Trauma Care
Opioid Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Karen Alexander, PhD principal investigator
Friends Research Institute, Inc.
Jan Gryczynski, PhD principal investigator
Friends Research Institute, Inc.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NavSTAR (Philly adaptation) in people with Opioid Use Disorder, run by Friends Research Institute, Inc. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Opioid Agonist Treatment (OAT) initiation (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06634277, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2025.